Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
6'-O-caffeoylarbutin is a natural phenolic compound and a standardized extract derived from the leaf buds of *Vaccinium dunalianum* Wight, a plant traditionally used in Chinese herbal medicine by the Yi people to treat rheumatism and stimulate blood circulation. Research utilizing zebrafish models has demonstrated that the compound possesses significant hypolipidemic and antithrombotic activities. Network pharmacology and molecular docking studies suggest that its therapeutic effects are mediated through the modulation of several key biological targets, including Matrix metalloproteinase-9 (MMP9), RELA (NF-kappa-B p65 subunit), and Matrix metalloproteinase-2 (MMP2). It is primarily investigated as a bioactive constituent of herbal teas and a potential nutraceutical for cardiovascular health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6'-O-caffeoylarbutin.